Home >  Registry
     
 
 Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Hepatitis C, Chronic

  • POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin).
    Not yet recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
    Recruiting


  • A Study of Combination Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response.
    Recruiting


  • SYREN Study: A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
    Recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
    Recruiting


  • IMPROVE Study(The Individualized Management with PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS® (Peginterferon alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.
    Recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Administered Alone or in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Have Participated in Previous PEGASYS Trials.
    Recruiting


  • A Study of the Influence of Ribavirin on the Initial Viral Response in Patients With Chronic Hepatitis C (CHC)
    Recruiting


  • A Study of Induction Dosing With PEGASYS (Peginterferon alfa-2a (40KD)) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C.
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a(40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
    No longer recruiting


  • APPROACH study: Outcomes Assessment of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC).
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection.
    No longer recruiting


  • A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin, With or Without Amantadine, in Treatment-Naive or Relapsing Patients With Chronic Hepatitis C (CHC)
    No longer recruiting


  • CHARIOT study - A Study of Induction Dosing with PEGASYS (Peginterferon alfa-2a (40KD)) and Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype-1
    No longer recruiting


  • PHOENIX study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.
    No longer recruiting


  • PINGU study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Early Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1/4/5/6
    No longer recruiting


  • PERFECT Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and Human Immunodeficiency Virus (HIV) Co-infection, Not Responding to PEGASYS Plus Ribavirin
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3
    No longer recruiting


  • CEE study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC)
    No longer recruiting


  • HELPS study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease
    No longer recruiting


  • A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
    No longer recruiting


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.
    Completed


  • A Study of the Pharmacokinetics of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) in Patients From Different Ethnic Backgrounds Infected With Chronic Hepatitis C (CHC)
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) Combination Therapy in Patients With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment.
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
    Completed


  • EAP (Expanded Access Program). A Study of PEGASYS (Peginterferon alfa-2a (40KD))Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC).
    Completed


  • REPEAT study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon alfa-2b (12KD))/Ribavirin Combination Therapy
    Completed


  • ACCELERATE Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.
    Completed


  • A Study of Roferon-A (Interferon Alfa-2a) in Patients With Chronic Hepatitis C
    Completed


  • OST study. A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Monotherapy and Combination Therapy With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC)
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Non-Responder Patients With Chronic Hepatitis C (CHC)
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin, With or Without Amantidine, in Non-Responding or Relapsing Patients With Chronic Hepatitis C (CHC)
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) plus Ribavirin in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection, With and Without Highly Active Antiretroviral Therapy (HAART)
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination with Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated with PEG-Intron + Ribavirin
    Completed


  • A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Treatment-Naive Patients With Chronic Hepatitis C (CHC).
    Completed


  • BeTTy study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Combination Therapy in Patients With Chronic Hepatitis C (CHC)
    Completed


  • Latino Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
    Completed


  • PEAK Study - A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
    Completed


    		•

    © 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement